ADMA Biologics, Inc.
ADMA
$9.37
-$0.18-1.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.04% | 10.99% | 19.63% | 27.62% | 43.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.04% | 10.99% | 19.63% | 27.62% | 43.58% |
| Cost of Revenue | -18.87% | -9.36% | 5.08% | 14.41% | 26.74% |
| Gross Profit | 31.89% | 29.34% | 33.35% | 41.12% | 62.77% |
| SG&A Expenses | 11.14% | 13.51% | 23.03% | 39.08% | 43.14% |
| Depreciation & Amortization | 80.91% | -20.00% | -62.37% | -78.18% | -84.31% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.15% | -1.41% | 10.87% | 21.28% | 30.81% |
| Operating Income | 39.10% | 36.05% | 37.74% | 41.91% | 79.43% |
| Income Before Tax | 49.28% | 46.58% | 45.30% | 112.35% | 270.19% |
| Income Tax Expenses | 174.34% | 162.08% | 149.65% | -1,127.41% | -1,558.01% |
| Earnings from Continuing Operations | -19.13% | -20.03% | -25.67% | 207.41% | 500.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.13% | -20.03% | -25.67% | 207.41% | 500.57% |
| EBIT | 39.10% | 36.05% | 37.74% | 41.91% | 79.43% |
| EBITDA | 37.08% | 34.31% | 35.71% | 39.00% | 71.97% |
| EPS Basic | -18.53% | -20.91% | -26.97% | 202.99% | 491.41% |
| Normalized Basic EPS | 44.40% | 40.22% | 43.36% | 52.25% | 109.51% |
| EPS Diluted | -15.03% | -16.44% | -23.24% | 195.87% | 495.16% |
| Normalized Diluted EPS | 46.70% | 42.25% | 45.23% | 53.04% | 108.76% |
| Average Basic Shares Outstanding | -0.99% | 1.37% | 2.53% | 3.52% | 4.14% |
| Average Diluted Shares Outstanding | -2.56% | -0.05% | 1.29% | 3.63% | 4.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |